This study focuses on patients with non-squamous non-small cell lung cancer (stage IIIB/IV) who have specific genetic changes including EGFR mutations, ALK rearrangement, or ROS1 fusion, and whose disease has progressed after previous targeted treatments. The study will test a combination of several cancer medicines: platinum-based chemotherapy (cisplatin or carboplatin), pemetrexed, atezolizumab, and in some cases, bevacizumab.
The main purpose is to determine how well this combination of medications works in treating the cancer, particularly by measuring how many patients respond to the treatment after 4 cycles. The study will look at two separate groups of patients – one group receiving bevacizumab and another group not receiving it – to better understand the effectiveness of different drug combinations.
During the study, participants will receive the medications through intravenous infusion. The treatment can continue for up to 36 months, depending on how well it works and how well it is tolerated. Throughout the study, patients will have regular check-ups to monitor their response to treatment and any side effects. The study will also track how long patients live without their disease getting worse and measure changes in cancer-related symptoms.



France